Oxford University Press

SHERPA: Yellow

People

  1. Postow
    Postow
  2. Busam
    Busam
  3. Shoushtari
    Shoushtari
  4. Begg
    Begg
  5. Orlow
    Orlow
  6. Coit
    Coit
  7. Barker
    Barker
  8. Bartlett
    Bartlett
  9. Panageas
    Panageas
  10. Smithy
    Smithy

Groups

  1. Melanoma Disease Management Team (90)
  2. Department of Medicine (65)
  3. Solid Tumor Oncology Division (57)
  4. Melanoma and Immunotherapeutics Service (45)
  5. Hematologic Malignancies, Division of (34)
  6. Department of Pathology and Laboratory Medicine (24)
  7. Epidemiology and Biostatistics (21)
  8. Biostatistics Service (20)
  9. GSK Faculty (20)
  10. Survivorship Research (19)
Search Within
  1. "Melanoma Disease Management Team"
Formats
  1. Journal Article (43)
  2. Meeting Abstract (43)
  3. Editorial (2)
  4. Conference Paper (1)
  5. Guidelines (1)
Groups
  1. Melanoma Disease Management Team (90)
  2. Department of Medicine (65)
  3. Solid Tumor Oncology Division (57)
  4. Melanoma and Immunotherapeutics Service (45)
  5. Hematologic Malignancies, Division of (34)
  6. Department of Pathology and Laboratory Medicine (24)

More Groups

People
  1. Alexander Shoushtari (24)
  2. Michael Postow (21)
  3. Klaus Busam (16)
  4. Colin Begg (8)
  5. Irene Orlow (8)
  6. Daniel Coit (7)

More People

Years
  1. 2025 (2)
  2. 2024 (13)
  3. 2023 (11)
  4. 2022 (6)
  5. 2021 (11)
  6. 2020 (6)

More Years

Publications
  1. Annals of Oncology (55)
  2. JNCI: Journal of the National Cancer Institute (10)
  3. American Journal of Clinical Pathology (4)
  4. American Journal of Epidemiology (4)
  5. Neuro-Oncology (4)
  6. Clinical Infectious Diseases (3)

More Publications

Results (90)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
    Meeting Abstract

    Rodon, J.; Chaney, M. F.; Cohen, J.; Garyantes, T. K.; Ishizuka, J.; Lin, J. J.; Lorusso, P.; Mita, A.; Mita, M.; Muller, C.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
    Meeting Abstract

    Burton, E.; Milton, D.; Simpson, L.; Tetzlaff, M.; Glitza, I. C.; Ross, M. I.; Gershenwald, J. E.; McQuade, J.; Wong, M.; Patel, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Chen, M. F.; Rosen, E.; Falcon, C.; Repetto, M.; Yang, S. R.; Chang, J.; Kris, M. G.; Rekhtman, N.; Donoghue, M.; Drilon, A.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Exocrine pancreatic insufficiency induced by immune checkpoint inhibitors
    Journal Article

    Satish, D.; Lin, I. H.; Flory, J.; Gerdes, H.; Postow, M. A.; Faleck, D. M.
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Association of functional, inherited vitamin D-binding protein variants with melanoma-specific death
    Journal Article

    Gibbs, D. C.; Thomas, N. E.; Kanetsky, P. A.; Luo, L.; Busam, K. J.; Cust, A. E.; Anton-Culver, H.; Gallagher, R. P.; Zanetti, R.; Rosso, S.; more...
    JNCI Cancer Spectrum (2023)

    Fulltext@MSK | Save
  • A rare case of rhabdomyosarcoma identified in a VRAM flap after lower extremity reconstruction
    Journal Article

    Fisher, M. H.; Woods, J. F. C.; Bartlett, E. K.; Nelson, J. A.
    Journal of Surgical Case Reports (2023)

    Fulltext@MSK | Save
  • Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600-or NRAS-mutant melanoma
    Meeting Abstract

    Lebbe, C.; Long, G. V.; Robert, C.; Hamid, O.; Atkinson, V. G.; Shoushtari, A. N.; Daud, A.; Bechter, O. E.; Schadendorf, D.; Sullivan, R. J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
    Meeting Abstract

    Sato, T.; Ikeguchi, A. P.; Nathan, P.; Carvajal, R. D.; Shoushtari, A. N.; Gajewski, T. F.; Hassel, J. C.; Rioth, M.; Leyvraz, S.; Daniels, G. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
    Meeting Abstract

    Schlaak, M.; Dummer, R.; Kirkwood, J. M.; Joshua, A.; Milhem, M.; Gastaud, L.; Mauch, C.; Yushak, M. L.; Lockwood, S.; Hayes, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
    Meeting Abstract

    Piulats Rodriguez, J. M.; Piperno-Neumann, S.; Rutkowski, P.; Nathan, P.; Hassel, J. C.; Espinosa, E.; de la Cruz Merino, L.; Ochsenreither, S.; Shoushtari, A. N.; Orloff, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save